Krystal Biotech (KRYS) CAO trades 12,500 shares in 10b5-1 plan

Rhea-AI Filing Summary

Krystal Biotech Chief Accounting Officer Kathryn Romano reported exercising stock options for 12,500 shares of common stock at an exercise price of $63.55 per share on February 9, 2026, then selling the same 12,500 shares in multiple open‑market trades at prices between $270.010 and $277.88 per share. Following these sales, she directly owned 18,568 shares of Krystal Biotech common stock.

The option exercise, share sales, and a 750‑share bona fide gift to a charitable donor‑advised fund were carried out under a pre‑arranged Rule 10b5‑1 trading plan that began on November 6, 2025 and is scheduled to run through August 31, 2026, subject to earlier termination under its terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROMANO KATHRYN

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M(1)		12,500	A	$63.55	31,818	D
Common Stock	02/09/2026		S		2,000	D	$270.5579(2)	29,818	D
Common Stock	02/09/2026		S		5,700	D	$271.6627(3)	24,118	D
Common Stock	02/09/2026		S		2,824	D	$272.5079(4)	21,294	D
Common Stock	02/09/2026		S		928	D	$273.7075(5)	20,366	D
Common Stock	02/09/2026		S		552	D	$274.6388(6)	19,814	D
Common Stock	02/09/2026		S		400	D	$275.68(7)	19,414	D
Common Stock	02/09/2026		S		96	D	$277.88(8)	19,318	D
Common Stock	02/09/2026		G(9)		750	D	$0	18,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$63.55	02/09/2026		M(1)			12,500	(10)	02/27/2032	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on November 6, 2025, and will terminate on August 31, 2026, subject to early termination in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

2. The transaction was executed in multiple trades ranging from $270.010 to $270.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. The transaction was executed in multiple trades ranging from $271.105 to $272.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

4. The transaction was executed in multiple trades ranging from $272.1275 to $273.070. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

5. The transaction was executed in multiple trades ranging from $273.160 to $274.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

6. The transaction was executed in multiple trades ranging from $274.305 to $274.815. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

7. The transaction was executed in multiple trades ranging from $275.445 to $275.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

8. The transaction was executed in a single trade.

9. Represents a bona fide gift of the Company's common stock to a charitable donor-advised fund.

10. The options vested ratably over a four-year period beginning on February 28, 2022.

Remarks:

	/s/ Kathryn Romano	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Krystal Biotech (KRYS) report for Kathryn Romano?

Kathryn Romano, Krystal Biotech’s Chief Accounting Officer, exercised options for 12,500 common shares at $63.55 per share and sold those shares in the open market. The trades occurred on February 9, 2026, at prices between $270.010 and $277.88 per share.

How many Krystal Biotech (KRYS) shares does Kathryn Romano hold after this Form 4?

After the reported transactions, Kathryn Romano directly holds 18,568 shares of Krystal Biotech common stock. This reflects exercising 12,500 options, selling 12,500 shares in multiple trades, and making a 750‑share bona fide gift to a charitable donor‑advised fund.

Was the Krystal Biotech (KRYS) insider sale by Kathryn Romano under a 10b5-1 plan?

Yes. The option exercise and share sales were executed under a Rule 10b5‑1 trading plan adopted by Kathryn Romano. The plan began on November 6, 2025 and is scheduled to terminate on August 31, 2026, subject to earlier termination as described.

What prices did Kathryn Romano’s Krystal Biotech (KRYS) share sales achieve?

The reported sales of 12,500 Krystal Biotech shares were executed in several trades at weighted average prices from about $270.5579 to $277.88 per share. Footnotes note underlying trade ranges, with one sale executed in a single trade at $277.88.

What stock option activity did the Krystal Biotech (KRYS) Form 4 show?

The filing shows exercise of a stock option (right to buy) for 12,500 shares of common stock at an exercise price of $63.55 per share. The option vested ratably over four years beginning on February 28, 2022, and expires on February 27, 2032.

Did the Krystal Biotech (KRYS) insider make any gifts of stock in this Form 4?

Yes. The Form 4 reports a bona fide gift of 750 shares of Krystal Biotech common stock, coded as a G transaction. The shares were donated to a charitable donor‑advised fund, reducing Kathryn Romano’s direct holdings accordingly.